Abstract
Cilengitide is a novel cyclic peptide that demonstrates anti-integrin activity. In laboratory studies, cilengitide binds with high affinity to the intergrins αvβ3 and αvβ5. It blocks proliferation of cells expressing this class of integrins and results in antiangiogenic and antitumor activity in animal models. Cilengitide has found a niche for clinical development in the population of patients affected by malignant glioma. The clinical evaluation has thus far found an overall high safety profile with limited toxicity and improved clinical outcomes in both recurrent and newly diagnosed glioma patients. This review intends to provide an overview of the preclinical development, summary of clinical trials to date, and update on ongoing and active therapeutic studies.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents